Rexahn Pharmaceuticals, Inc., of Rockville, Md., has announced that it has received approval to begin a phase II study for its lead oncology compound, Archexin (formerly known as RX-0201), in patients with advanced renal cell carcinoma.
Torisel (temsirolimus), an enzyme inhibitor, has received approval for advanced renal cell carcinoma (RCC) following a study of 626 patients.
SAN FRANCISCO—A new study found that converting from tacrolimus/sirolimus (TAC/SRL) to TAC/enteric-coated mycophenolic sodium (EC-MPS) may reduce proteinuria in renal transplant patients.
